AbbVie Inc
ABBV
ISIN US00287Y1091 / Valor 20145667
AbbVie Inc
UMushroom community rating:
About company
AbbVie Inc. is a global biopharmaceutical company dedicated to researching, developing, and marketing innovative medicines and medical solutions. With a workforce of over 50,000 employees across more than 70 countries, AbbVie focuses on addressing complex health challenges and improving the quality of life for people around the world. The company has a significant presence in research and development (R&D) and manufacturing, with facilities in approximately 20 countries. AbbVie's portfolio includes treatments for over 75 conditions, and its products reach around 50 million people annually in 175 countries. The company also emphasizes collaboration, maintaining over 250 partnerships with biotech firms, universities, nonprofits, and government organizations to advance scientific discovery. AbbVie's commitment to innovation is underscored by its development pipeline, which includes more than 80 compounds, devices, or indications.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.08.2024):
Second-Quarter EPS
AbbVie Inc. reported its second-quarter 2024 diluted EPS of $0.77 on a GAAP basis, reflecting a decrease of 32.5 percent compared to the previous year. The adjusted diluted EPS was $2.65, which represents a decrease of 8.9 percent. These results include an unfavorable impact of $0.52 per share related to acquired IPR&D and milestones expense.
Second-Quarter Net Revenues
In the second quarter of 2024, AbbVie Inc. delivered net revenues of $13.87 billion. This performance was driven by strong sales in key therapeutic areas, despite the challenges posed by market dynamics and competitive pressures.
First-Quarter EPS
For the first quarter of 2024, AbbVie Inc. reported a diluted EPS of $0.77 on a GAAP basis, marking an increase of 492.3 percent from the same period last year. The adjusted diluted EPS was $2.31, a decrease of 6.1 percent, which includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expense.
Full-Year 2023 EPS
AbbVie Inc. announced its full-year 2023 diluted EPS of $2.72 on a GAAP basis, a significant decrease of 59.0 percent compared to the previous year. The adjusted diluted EPS for the year was $11.11, reflecting a decrease of 19.3 percent, including an unfavorable impact of $0.42 per share related to 2023 acquired IPR&D and milestones expense.
Third-Quarter EPS
In the third quarter of 2023, AbbVie Inc. reported a diluted EPS of $1.00 on a GAAP basis, which is a decrease of 54.8 percent from the prior year. The adjusted diluted EPS was $2.95, showing a decrease of 19.4 percent, with an unfavorable impact of $0.04 per share related to acquired IPR&D and milestones expense.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
303471 M
Market cap (USD)
1,613,009
Daily traded volume (Shares)
172.425 / 167
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Lou Charlotte Wehrli
Luba Schoenig
EQUITIES OF THE SAME SECTOR
